Highlights Takeda Pharmaceutical Company Limited London S.E.

Equities

0RN3

JP3463000004

Market Closed - London S.E. Other stock markets 07:28:26 2019-03-26 EDT			5-day change	1st Jan Change
37.59 ^EUR	+6.79%		-.--%	-.--%

06-25	US CDC alerts healthcare providers of increase in dengue cases	RE
06-25	Takeda's Cancer Drug Gets European Commission Approval	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

US CDC alerts healthcare providers of increase in dengue cases	06-25	RE
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment	06-24	MT
Takeda Announces Approval of LIVTENCITY® by the Japanese Ministry of Health, Labour and Welfare	06-24	CI
Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)	06-23	CI
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia	06-22	CI
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla	06-21	MT
Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer	06-21	CI
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes	06-21	MT
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India	06-21	RE
Sun Pharma Signs Deal with Japan's Takeda to Commercialize Vonoprazan in India	06-20	MT
Sun Pharma Signs Non-Exclusive Patent Licensing Agreement with Takeda for Introducing Novel Gastrointestinal Drug, Voltapraz in India	06-20	CI
Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP	06-18	MT
Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting	06-18	CI
Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback	06-17	DJ
Sector Update: Health Care Stocks Decline Premarket Monday	06-17	MT
Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall	06-17	MT
Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints	06-17	MT
Takeda's Soticlestat Misses Goals in Phase 3 Epilepsy Studies	06-17	DJ
Takeda Pharmaceutical Company Limited Announces Topline Data from its Phase 3 SKYLINE and SKYWAY Studies Evaluating Soticlestat for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome	06-17	CI
Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome	06-17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Takeda Pharmaceutical Company Limited London S.E.

Equities

0RN3

JP3463000004

Highlights

Filters